A late-stage trial in The New England Journal of Medicine found that tezacaftor combined with ivacaftor was safe and effective compared with placebo in patients with cystic fibrosis who were homozygous for the Phe508del mutation.
Promising results for drug combo against cystic fibrosis
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.